HEPA News and Press, Hepion Pharmaceuticals Inc. From 09/07/23

2023-09-07 07:02:05 ET More on Hepion Pharmaceuticals Hepion Pharma NASH candidate meets phase 2 goal; up 68% Hepion climbs 39% on pre-clinical data for lead asset Hepion granted 180-day extension by Nasdaq to meet bid price requirements For furth...

EDISON, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH&#x...

American Bio Medica Corp. (ABMC) is expected to report for Q1 2024 Fonar Corporation (FONR) is expected to report for Q1 2024 Bank Hapoalim B.M. ADR (BKHYY) is expected to report for Q2 2023 QualTek Services Inc. (QTEKQ) is expected to report for Q2 2023 BIMI International Medical...

Hepion Pharmaceuticals Inc. (HEPA) is expected to report $-2.94 for Q2 2023

- Preclinical studies demonstrate rencofilstat may protect against NASH/NAFLD, shift the liver transcriptome and lipidome toward NASH resolution – - Cyclophilin B inhibition confirmed as an important target for treatment of NAFLD/NASH - EDISON, N.J., June 15, 2023 (GLOBE NE...

EDISON, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steato...

2023-05-26 11:27:39 ET Summary Shares of Hepion Pharmaceuticals more than doubled in value after reporting positive data from their phase 2 data evaluating rencofilstat as a NASH therapy. Since then, the stock has fallen greatly as the market has digested the results. Hepion&#...

EDISON, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial Intelligence (“AI”)-assisted therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH ...

2023-05-23 13:09:12 ET Gainers: CohBar ( CWBR ) +158% . Shuttle Pharmaceuticals ( SHPH ) +121% . Ocean Biomedical ( OCEA ) +108% . HeartCore Enterprises ( HTCR ) +110% . Lifecore Biomedical ( LFCR ) +66% . T Stamp ( IDAI ...

2023-05-23 08:45:00 ET Biocept ( BIOC ) 10% . Microvast Holdings ( MVST ) -20% plunges as Energy Department said to cancel DoE contract. Wave Life Sciences  ( WVE ) -13% crashes on decision to drop neurology asset on trial setback. ToughBuilt I...